	US 11,666,656 B2
	Polymeric conjugates and uses thereof
Ronit Satchi-Fainaro, Tel-Aviv (IL); Evgeni Pisarevsky, Tel-Aviv (IL); Anat Eldar-Boock, Tel-Aviv (IL); Dikla Ben-Shushan, Tel-Aviv (IL); Yana Epshtein, Tel-Aviv (IL); and Anna Scomparin, Tel-Aviv (IL)
Assigned to Ramot at Tel-Aviv University Ltd., Tel-Aviv (IL)
Appl. No. 16/79,123
Filed by Ramot at Tel-Aviv University Ltd., Tel-Aviv (IL)
PCT Filed Feb. 24, 2017, PCT No. PCT/IL2017/050236 § 371(c)(1), (2) Date Aug. 23, 2018, PCT Pub. No. WO2017/145164, PCT Pub. Date Aug. 31, 2017.
Claims priority of provisional application 62/299,423, filed on Feb. 24, 2016.
Prior Publication US 2019/0060477 A1, Feb. 28, 2019
Int. Cl. A61K 47/65 (2017.01); A61K 9/51 (2006.01); A61P 35/00 (2006.01); A61K 47/64 (2017.01); A61K 47/59 (2017.01); A61P 35/04 (2006.01); A61K 31/4184 (2006.01); A61K 31/506 (2006.01); A61K 31/4745 (2006.01)

CPC A61K 47/65 (2017.08) [A61K 9/5153 (2013.01); A61K 31/4184 (2013.01); A61K 31/506 (2013.01); A61K 47/59 (2017.08); A61K 47/645 (2017.08); A61P 35/00 (2018.01); A61P 35/04 (2018.01); A61K 31/4745 (2013.01); A61K 2300/00 (2013.01)]

26 Claims

1. A polymeric conjugate comprising a polymeric matrix having associated therewith a first agent and an additional agent, wherein said first agent is selected from selumetinib and a structural analog thereof, and wherein said additional agent is selected from dabrafenib and a structural analog thereof and acts in synergy with said first agent in the treatment of melanoma, wherein a mol ratio of said first agent and said additional agent is at least 3:1.